Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report

Abstract Background Ultiva™ contains the potent short-acting μ-opioid receptor agonist remifentanil hydrochloride, and it is commonly administered intravenously during general anesthesia. It is not approved for epidural or intrathecal use in clinical practice because it contains glycine as an acidic...

Full description

Bibliographic Details
Main Authors: Kota Nishimoto, Sachiyo Sakamoto, Makiko Mikami, Kiichi Hirota, Koh Shingu
Format: Article
Language:English
Published: SpringerOpen 2016-08-01
Series:JA Clinical Reports
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40981-016-0046-5
_version_ 1818351003896905728
author Kota Nishimoto
Sachiyo Sakamoto
Makiko Mikami
Kiichi Hirota
Koh Shingu
author_facet Kota Nishimoto
Sachiyo Sakamoto
Makiko Mikami
Kiichi Hirota
Koh Shingu
author_sort Kota Nishimoto
collection DOAJ
description Abstract Background Ultiva™ contains the potent short-acting μ-opioid receptor agonist remifentanil hydrochloride, and it is commonly administered intravenously during general anesthesia. It is not approved for epidural or intrathecal use in clinical practice because it contains glycine as an acidic buffer. However, at this moment, very limited information is available on epidural administration of Ultiva™. Case presentation We report the accidental administration of 300 μg of remifentanil and 2.25 mg of glycine into the epidural space after emergence from general anesthesia for distal pancreatectomy and the complete time course of its consequences. The respiratory depression occurred at 5 min after the administration, and complete loss of consciousness was observed at 8 min. The patient was re-intubated and underwent mechanical respiration. At 45 min (33 min after re-intubation), spontaneous respiration resumed, she was responsive to commands, and her orientation returned. She was extubated successfully. Conclusions These consequences might have resulted from the diffusion of the components of Ultiva™ into not only systemic circulation but also the cerebrospinal fluid. Moreover, the complex pathophysiology might be associated with remifentanil, as well as glycine present in Ultiva™.
first_indexed 2024-12-13T18:30:50Z
format Article
id doaj.art-ab78d04577594747ac893a6e709f798c
institution Directory Open Access Journal
issn 2363-9024
language English
last_indexed 2024-12-13T18:30:50Z
publishDate 2016-08-01
publisher SpringerOpen
record_format Article
series JA Clinical Reports
spelling doaj.art-ab78d04577594747ac893a6e709f798c2022-12-21T23:35:30ZengSpringerOpenJA Clinical Reports2363-90242016-08-01211310.1186/s40981-016-0046-5Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case reportKota Nishimoto0Sachiyo Sakamoto1Makiko Mikami2Kiichi Hirota3Koh Shingu4Department of Anesthesiology, Kansai Medical UniversityDepartment of Anesthesiology, Kansai Medical UniversityDepartment of Anesthesiology, Kansai Medical UniversityDepartment of Anesthesiology, Kansai Medical UniversityDepartment of Anesthesiology, Kansai Medical UniversityAbstract Background Ultiva™ contains the potent short-acting μ-opioid receptor agonist remifentanil hydrochloride, and it is commonly administered intravenously during general anesthesia. It is not approved for epidural or intrathecal use in clinical practice because it contains glycine as an acidic buffer. However, at this moment, very limited information is available on epidural administration of Ultiva™. Case presentation We report the accidental administration of 300 μg of remifentanil and 2.25 mg of glycine into the epidural space after emergence from general anesthesia for distal pancreatectomy and the complete time course of its consequences. The respiratory depression occurred at 5 min after the administration, and complete loss of consciousness was observed at 8 min. The patient was re-intubated and underwent mechanical respiration. At 45 min (33 min after re-intubation), spontaneous respiration resumed, she was responsive to commands, and her orientation returned. She was extubated successfully. Conclusions These consequences might have resulted from the diffusion of the components of Ultiva™ into not only systemic circulation but also the cerebrospinal fluid. Moreover, the complex pathophysiology might be associated with remifentanil, as well as glycine present in Ultiva™.http://link.springer.com/article/10.1186/s40981-016-0046-5Ultiva™RemifentanilGlycineEpidural spaceAccidental administration
spellingShingle Kota Nishimoto
Sachiyo Sakamoto
Makiko Mikami
Kiichi Hirota
Koh Shingu
Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
JA Clinical Reports
Ultiva™
Remifentanil
Glycine
Epidural space
Accidental administration
title Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
title_full Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
title_fullStr Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
title_full_unstemmed Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
title_short Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
title_sort accidental administration of the remifentanil formulation ultiva™ into the epidural space and the complete time course of its consequences a case report
topic Ultiva™
Remifentanil
Glycine
Epidural space
Accidental administration
url http://link.springer.com/article/10.1186/s40981-016-0046-5
work_keys_str_mv AT kotanishimoto accidentaladministrationoftheremifentanilformulationultivaintotheepiduralspaceandthecompletetimecourseofitsconsequencesacasereport
AT sachiyosakamoto accidentaladministrationoftheremifentanilformulationultivaintotheepiduralspaceandthecompletetimecourseofitsconsequencesacasereport
AT makikomikami accidentaladministrationoftheremifentanilformulationultivaintotheepiduralspaceandthecompletetimecourseofitsconsequencesacasereport
AT kiichihirota accidentaladministrationoftheremifentanilformulationultivaintotheepiduralspaceandthecompletetimecourseofitsconsequencesacasereport
AT kohshingu accidentaladministrationoftheremifentanilformulationultivaintotheepiduralspaceandthecompletetimecourseofitsconsequencesacasereport